Progress in the proxifan class: heterocyclic congeners as novel potent and selective histamine H3-receptor antagonists
作者:Sven Graßmann、Bassem Sadek、Xavier Ligneau、Sigurd Elz、C.Robin Ganellin、Jean-Michel Arrang、Jean-Charles Schwartz、Holger Stark、Walter Schunack
DOI:10.1016/s0928-0987(02)00024-6
日期:2002.5
analogues and their antagonist potencies at histamine H(3) receptors. The new compounds were tested for in vitro and in vivo H(3)-receptor antagonist potencies in different species as well as for H(3)-receptor selectivity vs. H(1) and H(2) receptors. In vitro, all compounds investigated proved to be potent H(3)-receptor antagonists in the rat as well as in the guinea-pig. In addition, they showed good
组胺H(3)受体与中枢神经系统(CNS)的几种疾病的病理生理至关重要。在H(3)-受体配体的其他家族中,proxifan类最近被描述为包含许多有效的组胺H(3)-受体拮抗剂,例如ciproxifan或imoproxifan。在本研究中,我们报告了新型杂环proxifan类似物的设计及其在组胺H(3)受体上的拮抗剂效力。测试了新化合物的体外和体内H(3)-受体拮抗剂在不同物种中的效力以及H(3)-受体对H(1)和H(2)受体的选择性。在体外,所有研究过的化合物均被证明是大鼠以及豚鼠中有效的H(3)-受体拮抗剂。此外,它们在小鼠体内显示出良好至高的口服中枢神经系统效力。特别,恶二唑衍生物24-26在体外具有纳摩尔的拮抗活性,在体内具有很高的效力(ED(50)= 0.47-0.57 mg / kg)。结果表明,另外的杂芳族部分可能分别充当昔洛芬或莫普昔芬的酮或肟部分的生物等排体,并且可能引起不同